BridgeBio Pharma Receives $500 Million Upon Acoramidis FDA Approval

BridgeBio Pharma, Inc. has recently shared certain preliminary financial details for the fiscal year ending December 31, 2024, as unveiled in a press release issued on January 13, 2025. The Company specifically highlighted that it received a significant sum of $500 million following the approval of acoramidis by the U.S. Food and Drug Administration.

However, it is essential to note that the information provided in this announcement falls under the category of unaudited and preliminary data. It may not encompass all necessary details for completely understanding the Company’s operational outcomes for the fiscal year concluded on December 31, 2024, or the financial state as of the same date. The Company is still in the process of auditing its financial statements for the year 2024, and modifications to the information shared in this press release may arise as a result of the audit.

Furthermore, on the same day, January 13, 2025, BridgeBio Pharma also presented a comprehensive business update at the 43rd Annual J.P. Morgan Healthcare Conference. The Company’s presentation slides from this event have been made publicly available on its website and have been attached to its current report on Form 8-K.

It is important to be aware that the current report on Form 8-K includes forward-looking statements, with the Company emphasizing facts that are subjunctive by nature and are anticipated under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company intends for these forward-looking statements to be protected by the safe harbor regulations provided for the same under the law.

While the Company is hopeful that its plans, intentions, and strategies, as exemplified in these forward-looking statements, are rational, there are no assurances that these plans will come to fruition or that the anticipated results will be realized. As with all investments, these plans and expectations are subject to various risks, uncertainties, and assumptions that can significantly impact the Company’s actual results.

It’s important to note that the information shared in the press release mentioned above and the subsequent presentations should not be considered “filed” for regulatory purposes as per Section 18 of the Securities Exchange Act of 1934, and are not to be incorporated by reference in any filings under the Securities Act of 1933 or the Securities Exchange Act, unless specifically indicated in such filings.

Included in this report are the exhibits encompassing the press release from January 13, 2025 (Exhibit 99.1), and the presentation slides from the J.P. Morgan Healthcare Conference (Exhibit 99.2).

Investors and stakeholders should bear in mind that the Company operates in a highly competitive and rapidly evolving environment and that new risks may surface over time as conditions change.

By: Brian C. Stephenson, Chief Financial Officer, BridgeBio Pharma, Inc.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read BridgeBio Pharma’s 8K filing here.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.